Company Overview
- Headquarters
- US
- Website
- calcilytix.com
- Employees
- 10
- Industry
- BioTech/Drugs
Financials & Stats
Revenue
$10B
Who is Calcilytix Therapeutics
Calcilytix Therapeutics is a clinical-stage biopharmaceutical company based in the United States. The company is an affiliate of BridgeBio Pharma and employs a team of 10 individuals. Calcilytix Therapeutics focuses on developing targeted therapies for disorders of calcium homeostasis. Their primary product candidate, encaleret, is an investigational small molecule designed to inhibit the calcium-sensing receptor. This therapy aims to restore normal serum calcium and lower urine calcium. Calcilytix Therapeutics' unique approach involves targeting the calcium-sensing receptor, a key regulator of calcium homeostasis. Their investigational therapy, encaleret, demonstrates the company's commitment to developing innovative treatments for calcium-related disorders. Visit calcilytix.com for more information.
Company Leadership
Companies Similar to Calcilytix Therapeutics
Analyze industry trends and opportunities by examining competitors and companies comparable to Calcilytix Therapeutics, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 10M | 18 | Arizona City, AZ | 1998 | |
| 10M | 9 | San Diego, CA | ||
| 10M | 6 | Campbell, CA | 2011 | |
| 10M | 2 | Torrington, WY | ||
| 10M | 1 | San Diego, CA | 2016 |